Bavarian Nordic Board's Support for Increased Takeover Offer
In a decisive move, the Board of Directors of Bavarian Nordic has reaffirmed its recommendation regarding the voluntary public takeover offer proposed by Innosera ApS. The consortium led by Nordic Capital and Permira is now offering an enhanced price for shareholders, marking a significant development for the company.
Details of the Takeover Offer
The takeover offer, originally outlined on August 26, presents a crucial opportunity for shareholders of Bavarian Nordic to maximize their returns. With the latest adjustments reflecting an attractive valuation, the Board believes that this offer is in the best interest of its shareholders.
Luc Debruyne, the Chair of the Board of Directors, emphasized, "Our commitment to delivering value to our shareholders remains steadfast. The board strongly endorses the offer given the current dynamics in the market and our assessment of the company’s intrinsic worth."
Understanding the Offer Period
The advisory from the Board comes on the heels of an extended offer period, which has given stakeholders additional time to consider this valuable proposition. As the offer period progresses, shareholders are encouraged to weigh the long-term benefits of accepting this takeover in their best interests.
Supplementary Statement Insights
With the release of a supplementary statement following the offer's second amendment, the Board has reiterated its solid endorsement. This statement shares insights into the factors influencing their decision, including a detailed analysis contrasting the increased offer price against prevailing market conditions. The Board encourages shareholders to review this documentation closely to understand the rationale behind this recommendation fully.
The Market Context
The offer arrives at a dynamic time in the market, as valuations fluctuate and investor interest in Bavarian Nordic remains high. The company has strategically positioned itself as a leader in innovative vaccine development, enhancing public health responses with a robust portfolio of vaccines. As a preferred supplier of mpox and smallpox vaccines, the company has consistently demonstrated its commitment to addressing public health challenges.
Next Steps for Shareholders
Shareholders are urged to stay informed about the developments related to this offer. Further detailed documents, including the Supplementary Statement, are available for review on Bavarian Nordic's website, which provides clarity on the offer's terms and the company’s outlook.
Contact Information for Inquiries
For any questions regarding the takeover offer, shareholders in Europe should reach out to Rolf Sass Sørensen, Vice President of Investor Relations, at rss@bavarian-nordic.com. He can provide further clarification and assist in addressing any concerns related to the offer. Meanwhile, those in the United States can connect with Graham Morrell from the Gilmartin Group for personalized assistance.
Why the Enhanced Offer is Attractive
The board's confidence in the tender offer stems from a thorough evaluation of Bavarian Nordic's market potential and strategic trajectory. The increased offer price reflects a recognition of the company's pivotal role within the vaccine industry, particularly as global demand for vaccines continues to rise. An endorsement by the Board indicates strong alignment with shareholder interests, supporting the notion that accepting the offer is a prudent choice at this juncture.
Frequently Asked Questions
What is the reason behind the Board's unwavering support for the takeover offer?
The Board believes that the enhanced offer accurately reflects Bavarian Nordic's value and potential, thus ensuring shareholders can realize substantial benefits.
When should shareholders make their decision regarding the offer?
Shareholders are encouraged to deliberate as the offer period extends, weighing the Board’s positive assessment and the opportunity for potential gains.
How can shareholders access further details about the takeover offer?
Details on the offer and supplemental statements are available on Bavarian Nordic's official website, designed for shareholder accessibility.
Who can shareholders contact for assistance with the offer?
Shareholders in Europe can contact Rolf Sass Sørensen, while those in the U.S. can reach out to Graham Morrell for guidance.
What should shareholders consider before accepting the offer?
Shareholders need to evaluate the offer's terms in context with their investment goals and the Board’s recommendations for the best path forward.
